Commercial Background
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Autoimmune conditions:
- 40 million people in EU and USA with >$20 billion in annual sales.
Serious allergies:
- 175 million individuals in EU and USA generating sales of >$23 billion per year.
Unmet need remains high because current treatments address only the symptoms (poorly in many cases) but not disease progression.
Multiple sclerosis key facts:
- 700,000 sufferers in EU and USA
- High economic burden - US cost estimated at $2-3 billion per year
- No satisfactory treatments available: limited efficacy with serious side effects
- High prices tolerated: Rebif (interferon beta-1a) average price is $22,875 p.a
Factor VIII intolerance key facts:
- 24,000 Haemophilia A sufferers in EU and USA – potential for Orphan Drug designation
- Serious bleeding disorder affecting primarily males managed with infusions of Factor VIII
- 20 to 30% of patients develop inhibitors of Factor VIII: decreases efficacy of treatment resulting in joint damage, brain damage and death
- Factor VIII sales exceeded $600 million in 2005